Quercetin stabilizes apolipoprotein e and reduces brain Aβ levels in amyloid model mice

Xilin Zhang, Jin Hu, Li Zhong, Na Wang, Longyu Yang, Chia-Chen Liu, Huifang Li, Xin Wang, Ying Zhou, Yunwu Zhang, Huaxi Xu, Guojun D Bu, Jiangxing Zhuang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Apolipoprotein E (apoE) is a major cholesterol carrier that regulates lipid homeostasis by mediating lipid transport from one tissue or cell type to another. In the central neural system (CNS), apoE is mainly produced by astrocytes, and transports cholesterol to neurons via apoE receptors, which are members of the low-density lipoprotein receptor family. The APOEϵ4 gene is a strong genetic risk factor for late-onset sporadic Alzheimer's disease (AD), likely through its strong effect on the accumulation of amyloid-β (Aβ) peptide. ApoE protein levels in cerebrospinal fluid (CSF) and plasma are reduced in APOEϵ4 carriers and in patients with AD. Furthermore, altered cholesterol levels are also associated with the risk of AD. Aβ accumulation, oligomerization and deposition in the brain are central to the pathogenesis of AD. Mounting evidence demonstrates that apoE and apoE receptors play important roles in these processes. Astrocyte-derived apoE is pivotal for cerebral cholesterol metabolism and clearance of Aβ. Thus, we hypothesized that increased apoE in the brain may be an effective therapeutic strategy for AD. We report here that quercetin can significantly increase apoE levels by inhibiting apoE degradation in immortalized astrocytes. Importantly, we show that oral administration of quercetin significantly increased brain apoE and reduced insoluble Aβ levels in the cortex of 5xFAD amyloid model mice. Our results demonstrate that quercetin increases apoE levels through a novel mechanism and can be explored as a novel class of drug for AD therapy.

Original languageEnglish (US)
Pages (from-to)179-192
Number of pages14
JournalNeuropharmacology
Volume108
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Apolipoproteins
Quercetin
Apolipoproteins E
Amyloid
Brain
Alzheimer Disease
Cholesterol
Astrocytes
Low Density Lipoprotein Receptor-Related Protein-1
Lipids
LDL Receptors
Oral Administration
Cerebrospinal Fluid
Homeostasis
Neurons
Peptides

Keywords

  • AD
  • ApoE
  • Quercetin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Quercetin stabilizes apolipoprotein e and reduces brain Aβ levels in amyloid model mice. / Zhang, Xilin; Hu, Jin; Zhong, Li; Wang, Na; Yang, Longyu; Liu, Chia-Chen; Li, Huifang; Wang, Xin; Zhou, Ying; Zhang, Yunwu; Xu, Huaxi; Bu, Guojun D; Zhuang, Jiangxing.

In: Neuropharmacology, Vol. 108, 01.09.2016, p. 179-192.

Research output: Contribution to journalArticle

Zhang, X, Hu, J, Zhong, L, Wang, N, Yang, L, Liu, C-C, Li, H, Wang, X, Zhou, Y, Zhang, Y, Xu, H, Bu, GD & Zhuang, J 2016, 'Quercetin stabilizes apolipoprotein e and reduces brain Aβ levels in amyloid model mice', Neuropharmacology, vol. 108, pp. 179-192. https://doi.org/10.1016/j.neuropharm.2016.04.032
Zhang, Xilin ; Hu, Jin ; Zhong, Li ; Wang, Na ; Yang, Longyu ; Liu, Chia-Chen ; Li, Huifang ; Wang, Xin ; Zhou, Ying ; Zhang, Yunwu ; Xu, Huaxi ; Bu, Guojun D ; Zhuang, Jiangxing. / Quercetin stabilizes apolipoprotein e and reduces brain Aβ levels in amyloid model mice. In: Neuropharmacology. 2016 ; Vol. 108. pp. 179-192.
@article{2de162d8f9db4352ae92eb6c42f7af47,
title = "Quercetin stabilizes apolipoprotein e and reduces brain Aβ levels in amyloid model mice",
abstract = "Apolipoprotein E (apoE) is a major cholesterol carrier that regulates lipid homeostasis by mediating lipid transport from one tissue or cell type to another. In the central neural system (CNS), apoE is mainly produced by astrocytes, and transports cholesterol to neurons via apoE receptors, which are members of the low-density lipoprotein receptor family. The APOEϵ4 gene is a strong genetic risk factor for late-onset sporadic Alzheimer's disease (AD), likely through its strong effect on the accumulation of amyloid-β (Aβ) peptide. ApoE protein levels in cerebrospinal fluid (CSF) and plasma are reduced in APOEϵ4 carriers and in patients with AD. Furthermore, altered cholesterol levels are also associated with the risk of AD. Aβ accumulation, oligomerization and deposition in the brain are central to the pathogenesis of AD. Mounting evidence demonstrates that apoE and apoE receptors play important roles in these processes. Astrocyte-derived apoE is pivotal for cerebral cholesterol metabolism and clearance of Aβ. Thus, we hypothesized that increased apoE in the brain may be an effective therapeutic strategy for AD. We report here that quercetin can significantly increase apoE levels by inhibiting apoE degradation in immortalized astrocytes. Importantly, we show that oral administration of quercetin significantly increased brain apoE and reduced insoluble Aβ levels in the cortex of 5xFAD amyloid model mice. Our results demonstrate that quercetin increases apoE levels through a novel mechanism and can be explored as a novel class of drug for AD therapy.",
keywords = "AD, ApoE, Aβ, Quercetin",
author = "Xilin Zhang and Jin Hu and Li Zhong and Na Wang and Longyu Yang and Chia-Chen Liu and Huifang Li and Xin Wang and Ying Zhou and Yunwu Zhang and Huaxi Xu and Bu, {Guojun D} and Jiangxing Zhuang",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.neuropharm.2016.04.032",
language = "English (US)",
volume = "108",
pages = "179--192",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Quercetin stabilizes apolipoprotein e and reduces brain Aβ levels in amyloid model mice

AU - Zhang, Xilin

AU - Hu, Jin

AU - Zhong, Li

AU - Wang, Na

AU - Yang, Longyu

AU - Liu, Chia-Chen

AU - Li, Huifang

AU - Wang, Xin

AU - Zhou, Ying

AU - Zhang, Yunwu

AU - Xu, Huaxi

AU - Bu, Guojun D

AU - Zhuang, Jiangxing

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Apolipoprotein E (apoE) is a major cholesterol carrier that regulates lipid homeostasis by mediating lipid transport from one tissue or cell type to another. In the central neural system (CNS), apoE is mainly produced by astrocytes, and transports cholesterol to neurons via apoE receptors, which are members of the low-density lipoprotein receptor family. The APOEϵ4 gene is a strong genetic risk factor for late-onset sporadic Alzheimer's disease (AD), likely through its strong effect on the accumulation of amyloid-β (Aβ) peptide. ApoE protein levels in cerebrospinal fluid (CSF) and plasma are reduced in APOEϵ4 carriers and in patients with AD. Furthermore, altered cholesterol levels are also associated with the risk of AD. Aβ accumulation, oligomerization and deposition in the brain are central to the pathogenesis of AD. Mounting evidence demonstrates that apoE and apoE receptors play important roles in these processes. Astrocyte-derived apoE is pivotal for cerebral cholesterol metabolism and clearance of Aβ. Thus, we hypothesized that increased apoE in the brain may be an effective therapeutic strategy for AD. We report here that quercetin can significantly increase apoE levels by inhibiting apoE degradation in immortalized astrocytes. Importantly, we show that oral administration of quercetin significantly increased brain apoE and reduced insoluble Aβ levels in the cortex of 5xFAD amyloid model mice. Our results demonstrate that quercetin increases apoE levels through a novel mechanism and can be explored as a novel class of drug for AD therapy.

AB - Apolipoprotein E (apoE) is a major cholesterol carrier that regulates lipid homeostasis by mediating lipid transport from one tissue or cell type to another. In the central neural system (CNS), apoE is mainly produced by astrocytes, and transports cholesterol to neurons via apoE receptors, which are members of the low-density lipoprotein receptor family. The APOEϵ4 gene is a strong genetic risk factor for late-onset sporadic Alzheimer's disease (AD), likely through its strong effect on the accumulation of amyloid-β (Aβ) peptide. ApoE protein levels in cerebrospinal fluid (CSF) and plasma are reduced in APOEϵ4 carriers and in patients with AD. Furthermore, altered cholesterol levels are also associated with the risk of AD. Aβ accumulation, oligomerization and deposition in the brain are central to the pathogenesis of AD. Mounting evidence demonstrates that apoE and apoE receptors play important roles in these processes. Astrocyte-derived apoE is pivotal for cerebral cholesterol metabolism and clearance of Aβ. Thus, we hypothesized that increased apoE in the brain may be an effective therapeutic strategy for AD. We report here that quercetin can significantly increase apoE levels by inhibiting apoE degradation in immortalized astrocytes. Importantly, we show that oral administration of quercetin significantly increased brain apoE and reduced insoluble Aβ levels in the cortex of 5xFAD amyloid model mice. Our results demonstrate that quercetin increases apoE levels through a novel mechanism and can be explored as a novel class of drug for AD therapy.

KW - AD

KW - ApoE

KW - Aβ

KW - Quercetin

UR - http://www.scopus.com/inward/record.url?scp=84969674439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969674439&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2016.04.032

DO - 10.1016/j.neuropharm.2016.04.032

M3 - Article

C2 - 27114256

AN - SCOPUS:84969674439

VL - 108

SP - 179

EP - 192

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -